Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Cumberland Pharmaceuticals, Clinigen sign US commercialization deal for Totect Cumberland Pharmaceuticals and Clinigen Group have signed an exclusive agreement to commercialize the oncology support drug, Totect (dexrazoxane hydrochloride) in the US.
Contract Research & Services > Contract Services > News
Novartis signs potential $1bn deal with Ionis and Akcea on cardiovascular treatments By PBR Staff Writer
Novartis has agreed to pay more than $1bn to Ionis Pharmaceuticals and its subsidiary Akcea Therapeutics for the rights to two cardiovascular drugs.
Contract Research & Services > Contract Services > News Dermavant licenses cerdulatinib from Portola for topical applications Dermavant Sciences has signed an exclusive worldwide licensing agreement with Portola Pharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Dermavant licenses cerdulatinib from Portola for topical applications
Dermavant Sciences has signed an exclusive worldwide licensing agreement with Portola Pharmaceuticals for the development and commercialization of cerdulatinib in topical applications beyond oncology.
Contract Research & Services > Contract Services > News
Bristol-Myers secures rights to PsiOxus’ armed oncolytic virus
By PBR Staff Writer
Bristol-Myers Squibb has signed an agreement worth up to $936m plus royalties to secure global rights to an armed oncolytic virus being developed by PsiOxus Therapeutics to treat solid tumors.
Contract Research & Services > Contract Services > News
VistaGen sublicenses rights to stem cell-related technologies to BlueRock Therapeutics
VistaGen Therapeutics has signed an exclusive sublicense agreement with BlueRock Therapeutics for rights to certain technologies relating to the production of cardiac stem cells for the treatment of heart disease.
Contract Research & Services > Contract Services > News
Grünenthal to buy rights to PNP drug from Astellas Pharma Europe
Grünenthal has agreed to acquire commercialization rights of Qutenza in Europe from Astellas Pharma Europe.
Contract Research & Services > Contract Services > News
AstraZeneca, Eli Lilly partner for another Alzheimer's drug
By PBR Staff Writer
Pharmaceutical giants AstraZeneca and Eli Lilly are expanding their collaboration to develop an experimental Alzheimer's drug.
Contract Research & Services > Contract Services > News
Sermonix signs licensing deal to further explore lasofoxifene for breast cancer treatment
Sermonix Pharmaceuticals has signed a licensing agreement to gain exclusive rights to Duke University intellectual property related to the use of lasofoxifene, its lead investigational drug, in the treatment of endocrine-resistant breast cancer.
Contract Research & Services > Contract Services > News
Purdue Pharma, AnaBios partner to advance research for non-opioid, non-NSAID compounds
Purdue Pharma and AnaBios have partnered to advance the research of non-opioid, non-NSAID compounds for the treatment of chronic pain.
Contract Research & Services > Contract Services > News
Aegerion Pharmaceuticals signs licensing deal with Amryt Pharma for Lojuxta
Novelion Therapeutics' subsidiary, Aegerion Pharmaceuticals has entered into a licensing agreement with Amryt Pharma (“Amryt”) for the exclusive rights to LOJUXTA (lomitapide) hard capsules in certain European and Middle Eastern territories.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests